A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Official title

A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease

Overview

This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's. The aims of the trial are to affirm potential therapeutic efficacy and safety observed in earlier clinical trials and assess the potential to modify the course of disease. The drug will be compared to placebo and administered orally to patients once a day for 78 weeks.

Detailed description

This study is a randomized, double-blind, placebo-controlled study of T3D-959 30mg in subjects with clinical mild-to-moderate Alzheimer's Disease and a biological diagnosis of AD pathology, as defined by a validated plasma biomarker (presently %p-tau217 plasma biomarker). This study is designed as a seamless group sequential design where estimates of treatment effect on cognitive and functional scales will be evaluated in an interim analysis by independent statisticians. The sample size will be re-estimated to ensure the study is sufficiently powered to demonstrate efficacy of T3D-959 in cognition and function.

Subjects will be assigned to one of two treatment arms (1:1 ratio) in a randomized, double-blind fashion, stratified by sex and ApoE4 genotype. Study medication will be taken once daily for 78 weeks. Safety/tolerability, efficacy and exploratory assessments will be evaluated for changes from baseline to end of treatment (78 weeks). Subjects will be followed for four weeks after the end of treatment.

Interventions

• Drug T3D-959
  Experimental: T3D-959 30 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength capsules contain 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest two size 0,
• Other Placebo Comparator
  Placebo used to compare to T3D-959 drug

Primary outcome measures

• Change from baseline to end of treatment in ADAS-Cog13 and ADCS-iADL [Time frame: 78 weeks]

Secondary outcome measures (4)

• Change from Baseline to End of Treatment in plasma AB42/40 ratio, in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology [Time frame: 78 weeks]
• Change from Baseline to End of Treatment in disease stage progression on the Clinical Dementia Rating Scale-Global (CDR-Global), in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology [Time frame: 78 weeks]
• Change from baseline to end of treatment in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB), in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology [Time frame: 78 weeks]
• Change from Baseline to End of Treatment on the integrated Alzheimer's Disease Rating Scale (iADRS), in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology [Time frame: 78 weeks]

Eligibility criteria

Inclusion criteria

• Male or female subject aged 50-90 years old inclusive at the time of Informed Consent
• Subject (or legal representative) and caregiver must sign an Informed Consent to participate in the study.
• Subject has a caregiver, an identified adult who, in the opinion of the investigator, has sufficient contact to knowledgeably report on the subject's cognition, function, behavior, safety, compliance and adherence. Same caregiver should, whenever possible, assist the subject throughout the duration of the trial
• Subject has a biological diagnosis of AD pathology, as assessed by a validated plasma biomarker (presently %p-tau217 plasma biomarker), according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening
• Subject has a clinical diagnosis of mild to moderate AD (Stage 4 or 5) according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening
• Meets criteria for mild-to-moderate cognitive impairment with Mini-Mental State Examination (MMSE) score of 14 through 26 at the screening visit.
• Modified Hachinski < 4 at screening
• Clinical Dementia Rating is 0.5 to 2.0 at screening
• Visual and auditory acuity adequate for neuropsychological testing
• Medical stability for this study as confirmed by review of records, comprehensive physical exam, neurological exam, and laboratory tests
• Washout and stability of all concurrent medication according to the exclusion criteria listed below
• Able to swallow oral medications

Exclusion criteria

• Subject has a current diagnosis of a significant psychiatric illness per the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V) including but not limited to major depressive disorder, anxiety disorders and is in an acute phase/episode; or the subject has a current diagnosis or history of schizophrenia or bipolar disorder; or has current signs of suicidality or history of suicide attempt
• Subject with untreated clinical depression at screening; Geriatric Depression Scale (GDS) Short Form > 9
• Evidence of clinically significant lesion(s) on brain MRI at Screening that could indicate a dementia diagnosis other than Alzheimer's disease
• Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter \[mm\] or less at the greatest diameter); a single macrohemorrhage >10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and <1 centimeter \[cm\] at their greatest diameter need not be exclusionary)
• Subject has a current diagnosis of a neurological disease other than AD, which has or could result in cognitive impairment, including, but not limited to, any of the following:

• History of clinically significant stroke or multiple strokes as ascertained by history and/or brain imaging findings, or history of TIA's within 12 months prior to baseline
• History of serious brain infection
• History of or current space occupying cerebral lesion
• History of clinically significant concussion or repeated head trauma associated with sustained cognitive impairment in the last 5 years
• Huntington's Disease
• Parkinson's Disease
• Dementia predominantly of a non-Alzheimer's type (vascular dementia, frontotemporal dementia, Parkinson's dementia, substance-induced dementia)
• Normal pressure hydrocephalus
• History of seizures (except for childhood febrile) or epilepsy
• With glycosylated hemoglobin (HbA1c) ≥ 10 at screening
• Subject with a diagnosis of unstable diabetes
• Subject with clinically significant thyroid disease at screening TSH >5 and abnormal T3/T4
• Subject has any evidence of hepatic impairment or renal insufficiency, including any of the following values at the screening visit:

• Serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) value that is twice the upper limit of normal
• A serum total bilirubin value that exceeds 2 mg/dL
• Serum creatinine level >1.5 mg/dL in men or > 1.4 mg/dL in women
• Positive urinalysis consistent with renal impairment
• Estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73m2
• Gamma glutamyl-transpeptidase (GGT) twice the upper limit of normal
• Subject is positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibodies at the screening visit
• Subject has a history of moderate or severe congestive heart failure, NYHA class III or IV, within 12 months prior to baseline
• Subject has experienced a previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 6 months prior to the baseline (visit 2)
• Subject has blood pressure reading at screening that is greater than 160/100 mmHg. Subjects with elevated BP will be allowed at the discretion of the principal investigator. Blood pressure will be measured after the subject has been supine for at least 5 minutes followed by repeat measurement after standing for at least 3 minutes. Subjects will be excluded if a significant diastolic (15 mmHg) drop in blood pressure or symptomatic presyncope occurred
• Subject has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal, endocrine, rheumatological, immunological, infection, skin and subcutaneous tissue disorder or metabolic disturbance
• Subject has a history of HIV infection
• Subject has a history of marijuana abuse or dependence (except topical CBD) within 1 year of the screening visit
• Subject has a history of alcohol, drug abuse or dependence (except nicotine dependence) within 2 years of the screening visit
• Subject has a history of cancer within 5 years of the screening visit (other than non-melanoma skin cancer, stable non-progressive prostate cancer not requiring treatment or in situ cervical cancer)
• Subject has any surgical or medical condition which may significantly alter the absorption of any drug substance including, but not limited to, any of the following:

• History of major gastrointestinal tract surgery (e.g. bariatric surgery)
• Currently active inflammatory bowel syndrome
• Female subject who is pregnant, nursing or of childbearing potential and not practicing effective contraception
• Subject is required to take excluded medications as specified in the Excluded Medications section below.
• Subject has a known or suspected intolerance or hypersensitivity to the study drug, closely related compounds, or any of their stated ingredients
• Subject resides in hospital or moderate to high dependency continuous care facility
• Evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

United States · 1 center

• T3D Therapeutics, Inc. — Durham

Identifiers

NCT: NCT06964230 · T3D959-301

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗